Advancedmolecular

DNA Repair in Detail

Overview

Cells suffer tens of thousands of DNA lesions daily (depurination, oxidation, replication errors). Layered repair systems handle them: direct reversal (photolyase, MGMT), base excision repair (BER) for small lesions, nucleotide excision repair (NER) for bulky ones, mismatch repair (MMR) for replication errors, and homologous recombination or NHEJ for double-strand breaks. Defects cause xeroderma pigmentosum, Lynch syndrome, and BRCA cancers.

Learning objectives

  • List the major repair pathways and their substrates
  • Explain NER and its link to XP
  • Explain MMR and Lynch syndrome
  • Compare HR vs NHEJ for double-strand breaks

Small lesions: BER and direct reversal

BER: DNA glycosylases remove damaged bases (uracil, oxidized bases), AP endonuclease cuts, polymerase fills, ligase seals; handles ~10,000+ lesions/cell/day. Direct reversal: photolyase splits thymine dimers (lost in placental mammals); MGMT removes O6-methylguanine (a chemotherapy resistance factor).

BER is the workhorse

Most daily damage is small base lesions handled quietly by BER.

Bulky lesions: NER

NER excises ~25-30 nt around bulky damage (thymine dimers, chemical adducts): XPC recognizes, TFIIH unwinds, XPG/XPF cut both sides, polymerase fills. Global-genome NER scans all DNA; transcription-coupled NER prioritizes active genes. XP patients (XPA-XPG mutations) develop childhood skin cancers; Cockayne syndrome affects transcription-coupled repair.

XP: sunlight is lethal

Without NER, UV damage accumulates catastrophically: XP children develop skin cancers before age 10.

Replication errors: MMR

MutS/MutL homologs (MSH2, MLH1, etc.) detect mismatches and small loops behind the replication fork, excise the new strand (identified by nicks in eukaryotes), and resynthesize. Lynch syndrome (HNPCC) from MMR mutations causes microsatellite instability and colorectal/endometrial cancers.

Microsatellite instability

MMR failure lets repeat tracts expand/contract: the MSI-high biomarker guiding immunotherapy.

Double-strand breaks: HR vs NHEJ

Homologous recombination (BRCA1/2, RAD51) uses the sister chromatid for error-free repair in S/G2. Non-homologous end joining (Ku70/80, DNA-PKcs) ligates ends anytime, often with small deletions: fast but mutagenic. BRCA-deficient cancers depend on backup pathways, enabling PARP inhibitor synthetic lethality.

Synthetic lethality

PARP inhibitors kill BRCA-mutant cancers by blocking their last repair option: a precision therapy from repair biology.

Key points

  • BER: small base lesions; NER: bulky adducts/dimers; MMR: replication mismatches
  • XP = NER defect; Lynch = MMR defect; BRCA = HR defect
  • HR is error-free (S/G2); NHEJ is fast but mutagenic
  • PARP inhibitors exploit synthetic lethality in BRCA cancers

Common misconceptions

✗ Myth: More repair is always better.

✓ Truth: Hyperactive repair can protect cancer cells from chemotherapy; MGMT overexpression causes alkylator resistance.

✗ Myth: All DNA damage causes mutations.

✓ Truth: Most lesions are repaired or trigger apoptosis/senescence; only misrepaired or unrepaired damage becomes mutation.

Practice questions

Q1. Nucleotide excision repair handles
  1. Uracil in DNA
  2. Bulky lesions like thymine dimers
  3. Mismatches
  4. Double-strand breaks
Answer: B.

NER excises ~25-30 nt patches around bulky damage.

Q2. Lynch syndrome is caused by defects in
  1. NER
  2. Mismatch repair
  3. BER
  4. Photolyase
Answer: B.

MMR mutations cause microsatellite instability and colorectal cancer predisposition.

Q3. PARP inhibitors work in BRCA-mutant cancers via
  1. Boosting immunity
  2. Synthetic lethality: blocking backup repair
  3. Increasing mutation
  4. Hormone blockade
Answer: B.

With HR gone, blocking PARP-mediated backup repair kills the cancer cells selectively.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why do BRCA mutations cause breast/ovarian cancer specifically?

Hormone-driven proliferation plus HR dependence in those tissues; the exact tissue specificity remains partly mysterious.

What is synthetic lethality?

Two individually survivable defects that together kill: BRCA loss + PARP inhibition leaves no double-strand break repair.

How does immunotherapy connect to MMR?

MSI-high tumors carry many neoantigens from unrepaired mutations, making them visible to checkpoint-blockade immunotherapy.